Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Malaria resulting from infection by Plasmodium vivax.
Biomarker and diagnostic research for Plasmodium vivax malaria has been reported in the published literature.
1 FDA-approved treatment is available for Plasmodium vivax malaria, including PRIMAQUINE PHOSPHATE (PRIMAQUINE PHOSPHATE, approved 1952).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
13 clinical trials registered, 6 recruiting. Interventions under study include drug therapy, other interventions, and biologic therapy. Pipeline includes 4 PHASE4, 4 PHASE3, 3 PHASE2. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07468513](https://clinicaltrials.gov/study/NCT07468513) |
Data assembled from 4 of 12 sources · Last updated Nov 17, 2026, 3:29 PM UTC
Common questions about Plasmodium vivax malaria
PRIMAQUINE PHOSPHATE
PRIMAQUINE PHOSPHATE |
— |
1952 |
Available |
Gene therapy approaches for Plasmodium vivax malaria have been reported in the published literature.
13 trials found
Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases. |
PHASE4 |
Menzies School of Health Research |
RECRUITING |
[NCT05788094](https://clinicaltrials.gov/study/NCT05788094) | ACT vs CQ With Tafenoquine for P. Vivax Mono-infection | PHASE4 | Shoklo Malaria Research Unit | RECRUITING |
[NCT06923592](https://clinicaltrials.gov/study/NCT06923592) | Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar | PHASE3 | London School of Hygiene and Tropical Medicine | RECRUITING |
[NCT04704999](https://clinicaltrials.gov/study/NCT04704999) | Southeast Asia Dose Optimization of Tafenoquine | PHASE4 | University of Oxford | RECRUITING |
[NCT05690841](https://clinicaltrials.gov/study/NCT05690841) | FocaL Mass Drug Administration for Vivax Malaria Elimination | PHASE3 | University of California, San Francisco | RECRUITING |
184 publications have been identified in PubMed for Plasmodium vivax malaria. Research spans Epidemiology / Natural History (24%), Basic Science / Preclinical (23%), and Clinical Trial Publication (17%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 44 | 24% |
Laboratory research | 42 | 23% |
Clinical study results | 31 | 17% |
Patient case studies | 26 | 14% |
Research summaries | 18 | 10% |
Testing and diagnosis research | 15 | 8% |
New treatment approaches | 8 | 4% |
Shanti PAI (2026). [PMID: 41378825](https://pubmed.ncbi.nlm.nih.gov/41378825/). *J Infect Dis*. [Diagnostic / Biomarker]
Sullivan DJ (2026). [PMID: 41662735](https://pubmed.ncbi.nlm.nih.gov/41662735/). *Am J Trop Med Hyg*. [Diagnostic / Biomarker]
Degaga TS (2026). [PMID: 41690325](https://pubmed.ncbi.nlm.nih.gov/41690325/). *Lancet Infect Dis*. [Clinical Trial Publication]
Shanks GD (2026). [PMID: 41805285](https://pubmed.ncbi.nlm.nih.gov/41805285/). *MSMR*. [Case Report / Case Series]
Chu CS (2026). [PMID: 41541400](https://pubmed.ncbi.nlm.nih.gov/41541400/). *Open forum infectious diseases*. [Epidemiology / Natural History]
Getachew H (2026). [PMID: 41928784](https://pubmed.ncbi.nlm.nih.gov/41928784/). *Res Sq*. [Basic Science / Preclinical]
Antonelli LR (2026). [PMID: 41932205](https://pubmed.ncbi.nlm.nih.gov/41932205/). *Curr Opin Immunol*. [Review / Meta-Analysis]
Donassolo RA (2026). [PMID: 41972120](https://pubmed.ncbi.nlm.nih.gov/41972120/). *Front Immunol*. [Basic Science / Preclinical]
Sadhewa A (2026). [PMID: 41953713](https://pubmed.ncbi.nlm.nih.gov/41953713/). *Lancet Reg Health West Pac*. [Epidemiology / Natural History]
K AV (2026). [PMID: 41505814](https://pubmed.ncbi.nlm.nih.gov/41505814/). *Journal of infection and public health*. [Epidemiology / Natural History]
AI-curated news mentioning Plasmodium vivax malaria
Updated Oct 6, 2026
A recent study highlights geographical variation in antimalarial drug resistance markers across the Southern African Elimination Eight region. This research is crucial for tailoring effective malaria treatment strategies in diverse populations.
A case report details a severe instance of Plasmodium vivax malaria complicated by secondary hemophagocytic lymphohistiocytosis, disseminated intravascular coagulation, and acute pancreatitis. This study highlights the complex clinical challenges associated with severe malaria cases.
Recent research highlights the coinfection of scrub typhus and malaria, shedding light on the complexities of managing these two endemic diseases. Understanding their interactions may inform better treatment strategies in affected regions.
Malaria cases in the U.S. have reached a 40-year high, with 1,925 cases reported in 2011, according to the CDC. This increase highlights the ongoing public health challenge posed by malaria in the country.